课题基金 / 基金详情

The Safety and Efficacy of Adalimumab for Pain Reduction in Individuals with Mucopolysaccharidoses: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial

The Safety and Efficacy of Adalimumab for Pain Reduction in Individuals with Mucopolysaccharidoses: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial
阿达木单抗用于减轻粘多糖症患者疼痛的安全性和有效性：1/2 期随机、双盲、安慰剂对照试验
批准号：
474599
负责人：
Mitchell John J
金额：
$85.57万
依托单位：
Research Institute of the McGill University Health Centre
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-07-01 至 2025-07-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=474599&lang=en
关键词：
Growth Mucopolysaccharidoses Pain Quality Of Life Rare Disease Tnf-Alpha

项目摘要

项目成果

Mitchell John J的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Mucopolysaccharidoses (MPS) is a group of rare diseases associated with skeletal abnormalities, joint stiffness, short stature, pain, and, in some subtypes, cognitive disabilities. Although treatments have improved life expectancy and cognitive outcomes f
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Safety and Efficacy of Adalimumab for Pain Reduction in Individuals with Mucopolysaccharidoses: A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial
海外基金